Trials / Recruiting
RecruitingNCT05909059
CAR T-cell Therapy in Patients With Renal Dysfunction
Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Northside Hospital, Inc. · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fludarabine | Received IV on Days -5 to -3 before CAR T cell therapy |
| DRUG | Cyclophosphamide | Received IV on Days -5 to -3 before CAR T cell therapy |
Timeline
- Start date
- 2024-11-18
- Primary completion
- 2026-08-31
- Completion
- 2027-08-31
- First posted
- 2023-06-18
- Last updated
- 2025-10-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05909059. Inclusion in this directory is not an endorsement.